Alnylam Pharmaceuticals, Inc. (ALNY) Stake Lessened by Wells Fargo & Company MN

Wells Fargo & Company MN lowered its holdings in Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) by 58.9% in the 3rd quarter, according to the company in its most recent filing with the SEC. The firm owned 135,318 shares of the biopharmaceutical company’s stock after selling 194,298 shares during the quarter. Wells Fargo & Company MN owned approximately 0.15% of Alnylam Pharmaceuticals worth $15,899,000 at the end of the most recent quarter.

Other hedge funds and other institutional investors have also added to or reduced their stakes in the company. QS Investors LLC raised its position in shares of Alnylam Pharmaceuticals by 59.7% in the 2nd quarter. QS Investors LLC now owns 2,408 shares of the biopharmaceutical company’s stock worth $192,000 after acquiring an additional 900 shares in the last quarter. The Manufacturers Life Insurance Company increased its position in Alnylam Pharmaceuticals by 7.0% during the 2nd quarter. The Manufacturers Life Insurance Company now owns 2,541 shares of the biopharmaceutical company’s stock valued at $203,000 after buying an additional 167 shares in the last quarter. Neuberger Berman Group LLC bought a new position in Alnylam Pharmaceuticals during the 2nd quarter valued at approximately $229,000. Fayerweather Charles bought a new position in Alnylam Pharmaceuticals during the 3rd quarter valued at approximately $230,000. Finally, Watch Point Trust Co bought a new position in Alnylam Pharmaceuticals during the 3rd quarter valued at approximately $235,000. Institutional investors and hedge funds own 88.39% of the company’s stock.

Shares of Alnylam Pharmaceuticals, Inc. (NASDAQ ALNY) traded up $1.02 during trading hours on Friday, hitting $129.07. The company’s stock had a trading volume of 796,481 shares, compared to its average volume of 1,060,000. Alnylam Pharmaceuticals, Inc. has a fifty-two week low of $35.98 and a fifty-two week high of $147.63. The stock has a market capitalization of $12,690.00, a price-to-earnings ratio of -24.58 and a beta of 2.98. The company has a quick ratio of 9.83, a current ratio of 9.83 and a debt-to-equity ratio of 0.14.

Alnylam Pharmaceuticals (NASDAQ:ALNY) last announced its earnings results on Tuesday, November 7th. The biopharmaceutical company reported ($1.34) earnings per share (EPS) for the quarter, missing the Thomson Reuters’ consensus estimate of ($1.23) by ($0.11). Alnylam Pharmaceuticals had a negative net margin of 664.70% and a negative return on equity of 46.94%. The business had revenue of $17.10 million for the quarter, compared to analysts’ expectations of $28.15 million. During the same quarter last year, the firm earned ($1.21) EPS. The firm’s quarterly revenue was up 24.8% on a year-over-year basis. analysts expect that Alnylam Pharmaceuticals, Inc. will post -5.21 earnings per share for the current fiscal year.

A number of analysts have commented on the company. Goldman Sachs Group raised Alnylam Pharmaceuticals from a “buy” rating to a “conviction-buy” rating in a report on Friday, December 15th. Instinet assumed coverage on Alnylam Pharmaceuticals in a report on Friday, September 15th. They issued a “reduce” rating and a $56.00 target price for the company. Piper Jaffray Companies reissued a “buy” rating and issued a $182.00 target price on shares of Alnylam Pharmaceuticals in a report on Friday, November 17th. B. Riley dropped their price target on Alnylam Pharmaceuticals to $220.00 and set a “buy” rating on the stock in a research note on Wednesday, November 8th. Finally, Morgan Stanley raised their price target on Alnylam Pharmaceuticals from $101.00 to $130.00 and gave the stock an “equal weight” rating in a research note on Thursday, November 9th. Three research analysts have rated the stock with a sell rating, seven have issued a hold rating, fifteen have assigned a buy rating and one has issued a strong buy rating to the stock. The stock currently has a consensus rating of “Buy” and a consensus price target of $121.20.

In related news, EVP Akshay Vaishnaw sold 33,666 shares of the business’s stock in a transaction that occurred on Monday, October 30th. The stock was sold at an average price of $121.46, for a total value of $4,089,072.36. Following the completion of the sale, the executive vice president now owns 45,201 shares in the company, valued at $5,490,113.46. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, SVP Laurie Keating sold 6,249 shares of the business’s stock in a transaction that occurred on Wednesday, December 20th. The shares were sold at an average price of $121.20, for a total value of $757,378.80. Following the completion of the sale, the senior vice president now owns 17,749 shares of the company’s stock, valued at approximately $2,151,178.80. The disclosure for this sale can be found here. Insiders have sold 274,075 shares of company stock valued at $35,356,089 in the last 90 days. Company insiders own 4.30% of the company’s stock.

ILLEGAL ACTIVITY WARNING: This piece of content was first posted by Dispatch Tribunal and is the property of of Dispatch Tribunal. If you are viewing this piece of content on another website, it was illegally copied and reposted in violation of international copyright laws. The original version of this piece of content can be accessed at https://www.dispatchtribunal.com/2018/01/13/wells-fargo-company-mn-has-15-90-million-stake-in-alnylam-pharmaceuticals-inc-alny.html.

Alnylam Pharmaceuticals Company Profile

Alnylam Pharmaceuticals, Inc is a biopharmaceutical company. The Company is engaged in the discovery, development and commercialization of ribonucleic acid (RNA) interference (RNAi) therapeutics. The Company is focused on the use of its N-acetylgalactosamine (GalNAc)-conjugate platform for delivery of small interfering RNAs (siRNAs).

Institutional Ownership by Quarter for Alnylam Pharmaceuticals (NASDAQ:ALNY)

Receive News & Ratings for Alnylam Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Alnylam Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply